Stay updated on Isatuximab in RVd Induction and Lenalidomide Maintenance Clinical Trial
Sign up to get notified when there's something new on the Isatuximab in RVd Induction and Lenalidomide Maintenance Clinical Trial page.

Latest updates to the Isatuximab in RVd Induction and Lenalidomide Maintenance Clinical Trial page
- Check2 days agoChange DetectedRevision tag updated from v3.6.4 to v3.6.5, indicating a small update to the page’s underlying version rather than substantive content changes.SummaryDifference0.0%

- Check9 days agoChange DetectedA new 2026 JCO publication citation for the GMMG-HD7 trial was added to the Publications section. Related-topic entries such as Multiple myeloma, related topics:, and MedlinePlus Genetics were removed from the page.SummaryDifference0.1%

- Check16 days agoChange DetectedExpanded related topics section to include 'Multiple myeloma' and 'MedlinePlus Genetics' as quick links. These additions provide readers with direct access to disease context and genetics resources related to the study.SummaryDifference0.1%

- Check24 days agoChange DetectedRevision: v3.6.4 was added, replacing the previous v3.6.3 tag. This reflects a maintenance update to the site rather than new content or user-facing features.SummaryDifference0.0%

- Check31 days agoChange DetectedThe related topics section has had entries removed: 'Multiple myeloma' and 'MedlinePlus Genetics'. This change narrows the list of linked topics shown alongside the study details and does not modify the trial information.SummaryDifference0.1%

- Check38 days agoChange DetectedDeleted the disease label 'Multiple myeloma' and the related topics entry 'MedlinePlus Genetics' from the page, removing explicit disease context and a related resource link.SummaryDifference0.1%

Stay in the know with updates to Isatuximab in RVd Induction and Lenalidomide Maintenance Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Isatuximab in RVd Induction and Lenalidomide Maintenance Clinical Trial page.